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Malaria afflicts 350–500 million people
annually, and this debilitating and deadly
infectious disease exacts a heavy toll on
susceptible populations around the globe.
Efforts to find effective, safe, and low-cost
drugs for malaria have sharply increased
in recent years. Almost all of these efforts
have focused on the cyclic blood stage of
the disease, partly because the parasites
can be easily maintained in culture
through addition of human red blood cells
to the growth medium, and partly because
blood stage infection causes malaria’s
characteristic symptoms. However, the
asymptomatic liver stage, which the par-
asite goes through only once in its life
history, presents the best opportunity for
developing drugs that both hit new targets
and also could be used in highly desirable
eradication campaigns. Recent research,
especially on the frequency of differentially
expressed genes in blood and liver stage
parasites, supports the feasibility of discov-
ering stage-specific drugs. Discovering
these drugs will require a high-throughput
liver stage phenotypic screen comparable
to the existing blood stage screens, and the
basic tools for such a screen have recently
been created.
Background
Humans have suffered from the burden
of malarial infections for thousands of
years, and the disease has greatly influ-
enced human evolution and history [1–3].
Malaria remains a devastating disease, and
in developing countries within Africa,
South America, and Asia, the size of its
burden has stifled economic growth and
development [2]. Despite successful erad-
ication campaigns in North America and
Europe, global cases of the disease show
little decline, and current improvements
rely on pyrethroid treated bed nets and
combination therapeutics containing arte-
misinin derivatives, both of which are
susceptible to emerging resistance [4].
Our ability to counter these vulnerabilities
with new agents is hampered by the
modest number of fully validated drug
targets and our limited understanding of
many aspects of parasite biology.
Today we understand that malaria is a
parasitic disease spread to humans
through the bite of an Anopheles mosquito.
During their obligatory blood meals,
infected female mosquitoes transmit pro-
tozoan parasites belonging to the genus
Plasmodium, and their proliferation in the
human host causes malaria’s symptoms
(Figure 1). Parasites from infected humans
are transmitted back to the mosquito host
in subsequent blood meals. The parasite
has a complicated life history. In the
mosquito gut, the parasites taken up from
the human host differentiate into male or
female gametes and produce a motile form
that migrates through the mosquito gut
wall and transforms into an oocyst that in
approximately 2 weeks produces and
releases thousands of sporozoites that
invade the mosquito’s salivary glands.
Mosquitoes inject sporozoites into the
human host during their blood meals,
and the sporozoites travel from the skin,
through the blood stream, to the liver.
Once in the liver, a sporozoite migrates
through several liver cells before it settles,
propagates, and produces thousands of
merozoites (reviewed in [5]) (Figure 1).
This exoerythrocytic phase produces no
host symptoms. But once the merozoites
infect red blood cells, the symptomatic
cyclical erythrocytic stage begins. Its waves
of bursting red blood cells and the invasion
of fresh red blood cells by the newly
released parasites produce malaria’s char-
acteristic symptoms. In total, the parasite’s
complicated life history involves two hosts
(mosquito and human), three major life-
stages (vector stage, liver stage, and blood
stage), and multiple forms. The human
stages entail vastly different numbers of
parasites as an initial infection can begin
with as few as 10 parasites from the
mosquito, followed by an expansion by a
factor of a thousand in the liver, and
ultimately an expansion to several trillion
in a mature blood stage infection [5].
P. falciparum is the deadliest of the
species of Plasmodium that infect humans,
and it accounts for the majority of malaria
infections and virtually all of the malaria-
related mortality worldwide [6]. P. vivax, P.
falciparum’s less deadly relative, contributes
substantially to malaria’s morbidity if not
mortality [7,8]. P. vivax and P. ovale can
hide out in the liver for prolonged periods
as hypnozoites, the latent hepatic stage,
which can cause relapsing malaria months
or even years after the initial infection [9].
Only primaquine clears both liver stage
parasites and latent stage hypnozoites,
while others target only the liver stage
parasites (atovaquone). Parasites can rap-
idly develop drug resistance but at unpre-
dictable and varying rates. There are
global concerns that the efficacy of all
currently used anti-malarial drugs will
erode, thereby creating a pressing need
to develop inexpensive yet effective agents
that can both treat and eradicate malaria.
Ironically, while current drug develop-
ment focuses on the well-studied blood
stage, the vector and liver stages present
better options for an eradication cam-
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The Past and Present of Anti-
Malaria Drug Discovery
Several drugs are used in various
combinations to treat malaria, but chloro-
quine and arteminsinin are arguably the
most abundantly used agents (reviewed in
[10]). Artemisinin comes from a plant
(Artemisia annua) used in traditional Chinese
medicine to treat fevers, and the com-
pound and its derivatives are presently
used worldwide in anti-malarial combina-
tion therapies (reviewed in [11]). Chloro-
quine was first synthesized early in the last
century, although its history can be traced
back to quinine from the bark of cinchona
trees, the new world’s ethnobotanical
contribution to the treatment of malaria.
Both artemisinin and chloroquine are
effective against the parasite’s blood stage.
Chloroquine targets heme polymerization
in the parasite’s food vacuole, while
artemisinin’s target is not known with
any certainty [12]. Neither arteminsinin
nor chloroquine is effective against the
liver stage in vivo. Drug-resistant Plasmo-
dium strains have become prevalent for the
currently used blood-stage anti-malarials
(reviewed in [13]) and reports of decreased
sensitivity towards artensunate in Cambo-
dia (reviewed in [11]) are particularly
worrisome.
The high risk of parasite resistance to
current therapies highlights the need for
replacements, and the most effective
replacements are likely to have new targets
and new chemotypes to which the parasite
has not yet developed resistance. The
search for these targets has been frustrated
by several factors. Unlike other systems,
the sequencing of Plasmodium genomes
provides few clues about essential genes
and/or processes as ,50% of the genome
contains open reading frames of unknown
function [14]. Determining gene function
has been hampered by the limited tools
available to carry out genetic manipula-
tions on the parasite. And to complete the
list of complicating factors, parasite pro-
teins are unusually difficult to express and
characterize.
In spite of these obstacles, current
approaches to discovering drugs with
new targets and chemotypes have had
some successes, which have come largely
from high-throughput screening of librar-
ies of structurally diverse small molecules.
Drug discovery screens can be either
target-based or phenotypic. Target-based
screens are often operationally simpler as
they can use pure proteins in a biochem-
ical assay, but they require selecting the
target prior to screening, and they will
only discover candidate molecules that
modulate the chosen target. Several tar-
get-based screens for suitable therapeutic
agents have been developed in the past 10
years. Histone deacetylases (HDAC)
[15,16], dihydroorotate dehydrogenase
(DHODH) [17,18], dihydrofolate reduc-
tase (DHFR) [19], heat shock protein 90
(Hsp90), and enzymes involved in fatty
acid biosynthesis [20,21] have been
among the most promising. While these
assays have provided compounds that
inhibit malaria growth, the lack of species
specificity between the Plasmodium and
human enzymes has limited drug devel-
opment.
Phenotypic screens involving whole cells
or even whole organisms have the obvious
advantage of being able to find new
targets. But they have the drawback of
being more, often much more, complicat-
ed to run. The only widely used pheno-
typic malaria screens involve blood stage
parasites and a growth/no growth pheno-
Figure 1. Parasite life cycle in the human host and mosquito vector. Sporozoites that are found in a mosquito’s salivary gland are injected
into the skin during the blood meal. The sporozoites that reach a blood vessel travel to the liver and traverse several cells before developing in a
hepatocyte. Here the parasite numbers grow significantly and they develop into a form that can invade red blood cells to initiate the cyclic asexual
stage. During this time some sexual gametocytes also develop and it is this form of the parasite that is taken up by a mosquito. The parasite invades
the mosquito’s midgut and develops into sporozoites that can infect a new human host. Graphic prepared by Ian Moores Graphics.
doi:10.1371/journal.ppat.1002178.g001
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that use varying reporters, but they all
exploit the ability of the parasite to be
grown in red blood cell culture. The first
published high-throughput assay utilized a
fluorescent DNA dye to quantify the
parasite’s growth, or lack thereof [22],
and most recently GlaxoSmithKline re-
ported the results of a high-throughput
screen measuring the parasite’s lactate
dehydrogenase (LDR) activity [23]. In
addition to these methods, luciferase
transgenic parasites [24], RNA probes
[25], antibody, and PCR-based [26]
detection methods have all been devel-
oped and have the potential to be
optimized toward the goal of anti-malarial
drug discovery. Phenotypic screens typi-
cally do not reveal an active molecule’s
mechanism, and linking a molecule to its
target can be very difficult [27]. Target
identification for phenotypic blood stage
screens has repeatedly identified already
known targets, like cytochrome bc1 [23].
In this regard, a recent blood stage
phenotypic screen by Novartis that iden-
tified a gene important for protein synthe-
sis, a P-type cation-transporter ATPase4,
is especially noteworthy [28]. In spite of
this and hopefully similar successes in the
future, we believe that the greatest oppor-
tunity for anti-malarial drug discovery lies
in the development of non-blood stage
parasite screens.
The Need for Anti-Malarial
Drugs Targeting the Liver Stage
Liver stage drugs have the potential to
hit new targets that are not present or
essential during the blood stages of
malaria, and these drugs would enjoy a
tactical advantage over blood stage drugs
because many fewer parasites are in-
volved, which should delay the develop-
ment of resistance [12]. Liver stage drugs
may also have activity against the hypno-
zoites of P. vivax, like primaquine, and
thereby prevent relapsing malaria. Despite
their apparent advantages, progress in
developing liver stage drugs has been very
limited, and this lack of success undoubt-
edly reflects the way drugs are currently
discovered: large numbers of molecules
are screened for blood stage activity and
only selected active candidates are
screened in the liver stage [12]. Prima-
quine, anti-folates, and atovaquone are
currently used drugs with liver stage
activity, but among these only primaquine
also has anti-hypnozoite activity.
Primaquine, a distant chemical relative
of chloroquine whose target has yet to be
determined, can inhibit both liver stage
infections and blood stage parasites in
vitro [29,30], and also prevent relapsing
malaria [9,31]. Unfortunately, its tenden-
cy to cause hemolytic anemia in patients
with glucose-6-phosphate dehydrogenase
deficiency, the most common human
enzyme deficiency, has severely restricted
its use (review in [32]). This deficiency is
most common in certain parts of Africa
(review in [32]), thus eliminating any hope
of using primaquine in an eradication
campaign. However, while primaquine
itself can never be a widely used anti-
malarial agent, its existence argues that
other molecules with better therapeutic
potential probably exist [12].
Additional evidence for the likelihood of
such drugs comes from transcriptional
profiling of blood and liver stage parasites.
Several recent reports have analyzed both
transcriptome and proteome expression
levels of malaria parasites in different life
stages. These studies uniformly revealed a
remarkable number of genes and proteins
that are expressed only during the liver
stage and thus represent likely stage-
specific drug targets (see Figure 2) [33–
35]. This marked difference between the
two stages is unsurprising as the different
parasite forms not only find, bind to, and
efficiently invade different host cells, but
also their replication rates differ by three
orders of magnitude. Interestingly, the
majority of the differentially expressed
liver stage genes encode hypothetical
proteins of unknown function [35], a
finding that also suggests that they could
reveal many new targets. A phenotypic
liver stage screen would provide the most
efficient path to discovering new drugs
that would hit these targets.
Prospects for a High-
Throughput Phenotypic Screen
for the Liver Stage
Our understanding of liver stage malar-
ia research has advanced considerably in
recent years, and the pieces for a high-
throughput screen for liver stage infection
appear to be in place. Arguably the most
important advance was developing an in
vitro culture system for liver stage infec-
tion. Now both human hepatoma cell lines
and primary hepatocytes can be infected
with sporozoites from different Plasmodium
species isolated from mosquitoes (review in
[36]), although the efficiency is still low.
Infection monitoring was initially done
with antibody imaging, which was very
time consuming [37–39]. Still other meth-
ods including RT-PCR [40,41] and fluo-
rescence-activated cell sorting (FACS)
using GFP-expressing parasites [42,43]
have emerged, and they allow both overall
parasite load and Plasmodium development
to be evaluated [44]. Plasmodium sporozoite
infection and quantification of liver cells
has even been accomplished in 96-well
format [45–47], suggesting low to medium
chemical screening is possible. Luciferase
transgenic parasites have been reported in
rodent Plasmodium strains (P. yoelii and P.
berghei) [48,49] and these bioluminescent
parasites reduce the time of analysis and
provide an efficient method to quantify
parasite load both in vitro and in vivo.
With both in vitro culturing and
reporting methods coming together for a
quantitative high-throughput liver stage
screen, we anticipate a shift from blood
stage to liver stage for high-throughput
phenotypic drug screens. It is likely that
the rodent malaria strains, including P.
yoelii and P. berghei, will be the first to be
evaluated as the essential tools are already
at hand. Of course, running an assay with
today’s tools requires the continual infec-
tion of liver cells with sporozoites and
dissection of infected mosquitoes to isolate
these sporozoites. Sporozoite harvesting
would currently limit any high-throughput
assay. In addition to being tedious,
parasite harvesting has an inherent vari-
ability as it is difficult to standardize
mosquito infections over long periods of
time [12]. Still, cryopreservation of large
batches of Plasmodium sporozoites may in
the future overcome this limitation [50].
Unfortunately, less progress has been
made towards reliable in vitro models for
hypnozoite assays. To date the only widely
used model to screen for anti-hypnozoite
activity is via the infection of rhesus
monkeys with P. cynomolgi sporozoites
(reviewed in [9]). Recently slow growing
P. cynomolgi hepatic forms were character-
ized after sporozoite infection of Macaca
fascicularis primary hepatocytes [51]. Sim-
ilarly, small parasite forms that may be
hypnozoites have also been reported after
infection of hepatoma cells with purified,
cyropreserved P. vivax sporozoites [50].
These reports represent an important first
step to establishing in vitro hypnozoite
models, but further validation of the
system is needed before screening efforts
can begin. In particular, re-activation of
such putative hypnozoites is required prior
to any further development. In that
context, in vitro infection of primary
hepatocytes or hepatoma cells for longer
periods of time must be optimized.
In summary, a high-throughput screen
against liver stage parasites should be an
attainable goal, although there are still
challenges to overcome for truly high
throughput. The urgent need for better
PLoS Pathogens | www.plospathogens.org 3 September 2011 | Volume 7 | Issue 9 | e1002178anti-malaria strategies and the eventual
eradication of malaria coupled with the
remarkable recent progress from several
laboratories make us optimistic about
achieving a new generation of liver stage
inhibitors in the near future.
Gene IDs for mentioned proteins are
2539 (glucose-6-phosphate dehydrogenase),
812272 (histone deacetylase), 9221804 (di-
hydrofolate reductase), 811999 (heat shock
protein 90), and 3885966 (dihydroorotate
dehydrogenase).
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